TP53 and prostate neoplasm: In all, these data demonstrate that low nM ganetespib inhibits proliferation of luminal Pten/Tp53 null PrCa stem/progenitor cells ex vivo and that ganetespib inhibits endogenous Pten/Tp53 null prostate tumor progression in vivo.